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To the Editor: We read with much interest the mini review
‘Treatment of immunoglobulin A nephropathy’ by Barrat
and Feehally,1 and were very pleased to note that, after many
debates between us at many meetings, Dr Feehally finally
accepts the results of our trial2,3 strongly suggesting the use of
steroids in patients with immunoglobulin A nephropathy
and persistent proteinuria (41 g/24 h), after aiming at a
blood pressure target value of 125/75 mmHg using anti-
hypertensive drugs, including angiotensin-converting enzyme
inhibitors and angiotensin II receptor blockers at maximum
doses and, if necessary, in combination. However, this
agreement clearly contradicts what is said in Table 1, which
contain no recommendation concerning the use of steroids in
patients with proteinuria levels of 41 g/24 h.
It is surprising that the abstract makes no mention of the
use of steroids for patients with proteinuria levels of 41 g/
24 h and refers to no evidence in favor of using steroids for
nephrotic immunoglobulin A nephropathy beyond the group
of minimal change nephropathy, whereas the text states that
‘the risk attributable to proteinuria is almost certainly a
continuum’. We agree that there is no evidence proving the
efficacy of steroids in this patient population, but no evidence
does not mean they should not be used, but just that there are
no randomized studies supporting their use. Nihilism while
awaiting the publication of randomized trials (which, to the
best of our knowledge, are not even planned) could be very
dangerous for the patients because, as the authors say
themselves, heavy proteinuria is also the most important factor
of progression in patients with immunoglobulin A nephropathy.
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We appreciate the interest of Dr Locatelli et al.1 in our
discussion of the treatment of IgA nephropathy.
It is not surprising, given the relative lack of robust
evidence, that there is a range of opinions about the
preferred treatment approaches to patients with IgA
nephropathy at risk for progressive renal failure, and Dr
Locatelli et al. have not interpreted our article as we had
intended.
We are in agreement that there is evidence that
increasing proteinuria marks a continuum of risk; how-
ever, the threshold of proteinuria 41 g/24 h was an entry
criteria for a number of treatment trials in IgA nephro-
pathy (including the trial of corticosteroids by our
correspondents). It might be appropriate to extend the
use of treatments effective for proteinuria 41 g/24 h to
patients with lesser degrees of proteinuria provided that
such treatments are well tolerated with very low toxicity.
The dosing regimen for corticosteroids studied by our
correspondents is substantial – over 6 months they gave 9 g
intravenous methylprednisolone with oral prednisolone
0.5 mg/kg/day. Although in their published study they state
this regimen was well tolerated by their patients and with
few adverse effects, in our experience such a regimen has
considerable short and longer term toxicity, which
strengthens our reluctance to recommend it in circum-
stances where its benefits have not been subject to
randomized controlled trial.
The crucial question is whether corticosteroids or other
immunosuppressive regimens give added benefit when
patients are treated to contemporary blood pressure goals
(125/75), with adequate blockade of the renin–angiotensin
system, using combination therapy with angiotensin
converting enzyme inhibitors and angiotensin receptor
blockers. In our opinion, the answer to this question is
uncertain since many of the studies we review in our
article, including that of Dr Locatelli et al., do not have
such contemporary best practice in the control limb of the
randomization. The analysis we provided in our article
emphasizes the need for caution since those few interven-
tion studies reporting rigorous blood pressure control with
effective renin–angiotensin blockade are in general those
least likely to show benefit for an additional treatment.
Our observations are not intended to criticize the
investigators who undertook these studies, since most were
designed and initiated when such standards of care for
blood pressure control and renin–angiotensin blockade
were not recognized; indeed, their contribution is much to
be respected when so few investigators around the world
have completed treatment trials in this common glomer-
ular disease.
As we recognize that corticosteroids remains the choice
of many nephrologists, we mentioned in the text of our
article that their use should be ‘considered’ but only in
circumstances where their use might be considered most
logical – if a patient still meets the entry criteria of the trial
of Dr Locatelli et al. (proteinuria 41 g/24 h) despite
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